Celldex Therapeutics CLDX Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's deferred tax assets and other non-current assets?
- Celldex Therapeutics (CLDX) reported deferred tax assets and other non-current assets of $15.43M in Q1 2026.
- How has Celldex Therapeutics's deferred tax assets and other non-current assets changed year-over-year?
- Celldex Therapeutics's deferred tax assets and other non-current assets increased by 48.3% year-over-year, from $10.41M to $15.43M.
- What is the long-term trend for Celldex Therapeutics's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Celldex Therapeutics's deferred tax assets and other non-current assets has grown at a 218.1% compound annual growth rate (CAGR), from $41K to $13.36M.